RT Journal Article
SR Electronic
T1 Exposure to Renin-Angiotensin System Inhibitors Is Associated with Reduced Mortality of Older Hypertensive Covid-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.15.20247999
DO 10.1101/2020.12.15.20247999
A1 Gori, Mauro
A1 Berzuini, Carlo
A1 D’Elia, Emilia
A1 Ghirardi, Arianna
A1 Bernardinelli, Luisa
A1 Gavazzi, Antonello
A1 Balestrieri, Giulio
A1 Giammarresi, Andrea
A1 Trevisan, Roberto
A1 Di Marco, Fabiano
A1 Bellasi, Antonio
A1 Amoroso, Mariangela
A1 Raimondi, Federico
A1 Novelli, Luca
A1 Magro, Bianca
A1 Mangia, Gianpaolo
A1 Lorini, Ferdinando L.
A1 Guagliumi, Giulio
A1 Fagiuoli, Stefano
A1 Parati, Gianfranco
A1 Senni, Michele
YR 2020
UL http://medrxiv.org/content/early/2020/12/17/2020.12.15.20247999.abstract
AB From a cohort of 1352 consecutive patients admitted with coronavirus disease (Covid-19) to Papa Giovanni XXIII Hospital in Bergamo, Italy, between February and April 2020, we selected and studied 688 patients with arterial hypertension (254 deaths) to assess whether use of renin-angiotensin system inhibitors (RASIs) prior to hospital admission affects mortality from Covid-19. Prior use of RASIs was associated with a lower mortality in the over-68 group of patients, whereas no evidence of a similar effect (whether protective or adverse) was found in the younger group. There was positive relative excess due to a statistically significant (p =0.001) interaction between prior RASI exposure and an age greater than 68 years, corresponding to a positive relative excess risk. Next we used the subgroup of 411 hypertensive patients older than 68 yrs to separately assess the effects prior use of two RASI drug subclasses, angiotensin-converting enzyme inhibitors (ACEIs) and angiogiotensin receptor blockers (ARBs), by comparing these two exposures with no exposure to RASIs. We found both prior use of ACEIs and prior use of ARBs to be associated with a lower Covid-19 mortality, after adjusting for 32 medical history variables via propensity score matching. (ORACEI = 0.57, 95%CI 0.36 to 0.91, p =0.018) (ORARB = 0.49, 95%CI 0.29 to 0.82, p =0.006).Competing Interest StatementMG: consulting fees from Novartis, Boehringer, and Menarini RT: received lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi, and has participated in advisory panels for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi. SF: speaker's bureau and advisory board for Gilead, Abbvie, MSD, Novartis, Astellas, Intercept, Kedrion, Bayer. MS: Bayer, Novartis, Boehringer, Astrazeneca. REMAINING AUTHORS: noneFunding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NECESSARY APPROVAL was obtained from the Bergamo Ethics Committee (n. 37/2020) with operating center at the Papa Giovanni XXIII Hospital of Bergamo, which has capacity to give its opinion on studies conducted in a number of health care structures in the Bergamo area of the north-italian region Lombardia, including the mentioned hospital, plus ten Aziende Socio Sanitarie Territoriali and fourteen Agenzie di Tutela della Salute. In conformity with local protocol, consent was obtained from the patient.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be requested to the Research Foundation of Bergamo Hospital, Bergamo, Italy (CovidLab)